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marketing activity by brand name drugs. Estimates were small, significant, and 
positive (feed-forward neural networks indicated an even stronger positive relation-
ship between brand and generic approvals), suggesting that the presence of generic 
drugs might further innovation. ConClusions: It was shown that market size does 
affect the rates at which pharmaceuticals aim to bring their products to the market. 
While brand manufacturers react positively to increased market size, weak property 
rights do not appear to affect innovation output negatively.
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objeCtives: Oncology trials increasingly permit switching from standard care (SC) 
to the new treatment following disease progression. Methods to remove the effect 
of the active treatment in the SC arm are used by HTA agencies to estimate what 
the effect of the SC would’ve been had crossover not occurred. One method is using 
RPSFT models to derive counterfactual survival times without crossover. For CE 
modeling, these counterfactual survival times need to be parametrically extrapo-
lated to estimate life expectancy. It is known that the RPSFT approach introduces 
additional uncertainty and e.g. the standard error of a hazard ratio calculated from 
counterfactual survival times needs to be inflated. Traditional methods of para-
metric survival analysis don’t account for this increased uncertainty which could 
influence allocation decisions. Methods: A dataset of 400 patients was simulated 
assuming a Weibull distribution for PFS and OS with 70% of the patients in the SC 
arm switching after progression. Life expectancy was calculated in two scenarios. In 
scenario 1 the RPSFTM adjusted OS had Weibull parameter estimates and covariance 
calculated directly from the counterfactual survival times. In scenario 2 the data 
was bootstrapped 1000 times. For each iteration a new RPSFT model, associated 
counterfactual survival times and Weibull functions were fitted. The mean and 
covariance of these 1000 parameter estimates was taken. Results: Mean incre-
mental life expectancy after adjusting for cross-over was the same with and without 
bootstrapping. When PSA was run, larger confidence intervals in the scenario with 
bootstrapping indicated, the traditional approach failed to account for the increased 
uncertainty and underestimated the probability of the new treatment being less 
efficacious (0.4% without compared to 13.4% with bootstrapping). ConClusions: 
Failing to appropriately reflect the uncertainty underlying parameter estimates of 
crossover adjusted survival times could impact HTA decisions when appraisals are 
based on the likelihood of a treatment being cost effective.
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objeCtives: Reporting of survival outcomes from clinical trials is often limited to 
median survival times, hazard ratios, Kaplan-Meier curves and numbers at risk. 
The numerical results are not always sufficient for meta-analysis and cost-effec-
tiveness analysis. Further information can be obtained by digitizing and analysing 
the Kaplan-Meier curves. The most basic analysis approach is to fit a non-linear 
model to the Kaplan-Meier curve and use this to estimate parameters such as the 
mean survival time. Methods have recently been developed for estimating individual 
patient data (IPD) from Kaplan-Meier curves. Once individual patient data is esti-
mated, standard survival analysis approaches can be used to estimate parameters 
and also provide estimates of uncertainty in the curve fits. The objective of this 
study was to review the methods commonly used and assess the impact of the 
improved methods, where IPD is estimated, on the inferences drawn. Methods: 
We conducted a systematic review of the methods that have been used in NICE HTAs 
to obtain data from published Kaplan-Meier curves. We examined the frequency 
of each method, how results were used and any feedback from Evidence Review 
Groups. Improved methods, estimating IPD, were applied to a selection of studies 
where this was not conducted in the original analysis. The impact of the improved 
methods on the conclusions of the studies was assessed. Results: The review 
showed that most HTAs used non-linear models to approximate the Kaplan-Meier 
curves. It also showed that the improved methods, estimating IPD, can have a sig-
nificant impact on conclusions drawn from survival results. ConClusions: The 
estimation of IPD from Kaplan-Meier curves is a valuable method that is currently 
underutilised. It has the potential to provide better estimates of survival param-
eters and to improve the characterisation of uncertainty in such estimates. This is 
especially important when survival curves are extrapolated.
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objeCtives: Evolution of asthma disease severity over time can be highly depend-
ent on the prescription patterns and drug compliance of patients. The purpose of 
the modeling is to analyze longitudinal observational data of cohort of asthma 
patients to describe and quantify the dynamics of adherence, prescriptions, and 
outcomes and their interaction over time. Methods: We explored and analyzed 
5 different observational studies following asthma patients in France over up to 
2 years. Main patients’ demographics along with prescriptions, ACT and 3-level 
GINA control scores could be defined every quarter and exacerbations at a given 
quarter were adjucated based on hospital admissions. Medication possession 
ratios could be defined quarterly and used as a proxy for adherence. A patient-
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objeCtives: While the follow-up time on Ipilimumab trials is in excess of 4 years, 
HTA models often require survival to be extrapolated to 10 years and beyond. 
However, patient level data on prognostic factors are rarely available; hence 
extrapolation methods assume a homogeneous study population and are based 
on statistical considerations only. Such approaches are criticized for disregarding 
clinical reality and may be biased. In this study a survival extrapolation model 
that accounted for heterogeneity was developed based on both statistically and 
clinically relevant considerations. The method was applied on survival data in 
patients with Metastatic Melanoma. Methods: Survival data were taken from 
a randomized controlled clinical trial that compared dacarbazine plus placebo 
versus dacarbazine plus ipilimumab. Two parametric models were explored to 
extrapolate survival: a model assuming no heterogeneity in patients and another 
model that divided patients into three subgroups based on cancer stage observed 
at baseline and additionally included subpopulations of a priori unobserved long-
term survivors. Survival of the subpopulations was extrapolated and summed 
to obtain survival in the overall population. Subgroup formation was guided by 
expert opinion of oncologists. The statistical and clinical validity of the models 
were assessed. Results: Among commonly used distributions (exponential, 
Weibull, lognormal) the lognormal distribution fitted the survival data best in 
the no-heterogeneity model whereas Weibull distribution was used for the het-
erogeneity model. For statistical validity, both models fitted the data reasonably 
well. However, the no-heterogeneity model underestimated the long tail of the 
survival curves. The no-heterogeneity model implied decreasing mortality over 
time while the heterogeneity model implied increasing mortality, which is more 
clinically relevant. ConClusions: The no-heterogeneity model fitted the data 
reasonably well but was not relevant for extrapolation from a clinical perspective. 
The heterogeneity model captured the long tail of the survival curve best, and 
provided a statistically and clinically relevant model.
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objeCtives: A three-state Markov model for cost-effectiveness analysis of cancer 
treatments requires information on both progression-free survival (PFS) and over-
all survival (OS). However, data is not always available on both of these outcomes. 
The objective of this study is to perform a Bayesian bivariate indirect comparison 
meta-analysis (BICMA) to obtain estimates of both PFS and OS for use in a cost-
effectiveness analysis when data on these outcomes is incomplete. Methods: In 
a UK Health Technology Assessment report on cost-effectiveness assessment of 
docetaxel with prednisone/prednisolone for the treatment of hormone-refractory 
metastatic prostate cancer, a two-state Markov model was specified using OS data 
from a single randomised controlled trial that did not report PFS. We propose the 
use of a Bayesian BICMA model that jointly estimates OS and PFS, and which in turn 
allows for the specification of a three-state Markov model incorporating a post-pro-
gression phase. Survival data for the trials included in the BICMA were reconstructed 
from survival curves, presented in the articles reporting the trials, using the method 
proposed by Guyot et. al. (BMC Med Res Methodol 2012;12:9) using the DigitizeIt and 
R software. Results: The Bayesian BICMA model was designed to jointly model 
the correlated outcomes: OS and PFS using either non-informative or informative 
prior distribution on the correlation between the outcomes. An informative prior 
distribution on the correlation between PFS and OS was based on external evidence 
using prostate cancer trials presented in Halabi et. al. (Clin Oncol 2009;27(17):2766-
71). Modelling the correlated outcomes jointly using this bivariate model allows 
prediction of PFS for the comparison of interest. ConClusions: In the absence of 
evidence on PFS, required for the specification of a three-state Markov model, the 
proposed method allows PFS to be constructed thus eliminating the need to reduce 
the cost-effectiveness analysis to a two-state Markov model.
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objeCtives: To examine factors determining the level of innovation in an organisa-
tion, examining two factors – market size and the strength of intellectual property 
rights for a particular drug class Methods: The pharmaceutical industry is used 
as a case study as it not only relies heavily on R&D, but, with the division between 
brand name and generic drugs, can provide insight into how the removal of intel-
lectual property rights might affect innovation. The estimation models were based 
on an economic model for innovation and market size developed by Acemoglu and 
Linn (2004). Drug approval data obtained from the US FDA was used for the innova-
tion variable; a measure for market size was constructed using prescribed medi-
cines expenditure data from the US Medical Expenditure Panel Survey. The analysis 
focussed on examining the relationships between the variables using various statis-
tical estimation techniques, starting with a simple OLS log-log model, more general 
negative binomial and gamma models, as well as fully flexible non-linear smoothing 
regressions in the form of feed-forward neural networks. Results: Brand name 
approvals increased by 2.64% and generic approvals by 4.2% for a 1% increase in 
income-based market size. The presence of generic drugs and, thus, weak intel-
lectual property rights did not appear to have a negative effect on research and 
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influence the outcome of treatment. The objective was to assess patient preferences 
on treatments for ED by applying Conjoint Analysis. Methods: Seven attributes 
were selected through a literature review and a consultation with 25 patients treated 
of ED and 5 experts: effectiveness (E), rapidity of onset (R), duration of effect (D), 
adverse events (AE), methods of administration (MA), price (P) and interaction with 
alcohol and food (I). 3 groups of scenarios were selected using “Orthogonal Design”: 
Phase 1, 9 scenarios with 4 attributes (R, D, MA, I); Phase 2, 16 scenarios with the 7 
attributes; Phase 3, 9 scenarios with 4 attributes (E, MA, P, I). It was applied the “Order 
of simulated preference” method by using cards with symbols and text. Interactions 
of age, comorbidity and frequency of sexual intercourses with preferences were 
studied. Results: The set of 16 scenarios was very difficult for patients. A total 
of 314 patients participated in Phase 1, 99 in Phase 2 and 178 in Phase 3. Order of 
preferred attributes: Phase 1: MA (57.99%), D (16.68%), I (14.57%) y R (10.76%); Phase 
2: MA (40.53%),E (21.98%), R (8.98%), P (8.11%), D (7.46%), AE (6.67%),I (6.25%); Phase 
3: MA (53.9%), I (22.45%), P (12.50%), E (11.14%). The preferred MA in the 3 phases 
was the orodispersible tablet with reference to pill and injectable. No statistically 
significant associations were found with age, comorbidity and frequency of sex-
ual intercourse. ConClusions: . Patients gave more importance to the attribute 
“method of administration” in any of the three phases performed. The preferred 
MA was orodispersible tablet over pill and injectable.
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objeCtives: The EQ-5D-3L descriptive classification defines a total of 243 health 
states which presents a problem when seeking to establish social preferences. As 
it would be challenging to value all 243 health states, a subset is chosen but the 
basis for this selection varies across national valuation studies. The aim of this 
study was to choose health states based on the most commonly found health states 
experienced by the Irish population. Methods: EQ-5D data from four different 
datasets were combined to determine what health states are prevalent in Ireland. 
Data from a general population study of health (SLAN), an over 70 population cohort, 
a rheumatoid arthritis and psoriatic arthritis cohort. The most commonly experi-
enced health states were determined and these were arranged on a 5 dimensional 
lattice. Health states were chosen using the Manhattan distance metric. Results: 
A total of 12,520 ratings of self-reported EQ-5D health states were included. Fifty 
two per cent of the cohort had perfect health (11111). Ninety five per cent of states 
include at least one ‘1’ and no ‘3’. 126/243 health states were not experienced in 
these datasets. The Manhattan distance between health states was measured. The 
imposition of such a metric facilitated the identification of clusters of states and 
associated centroids. Distance sampling was used to identify states within the clus-
ters. A simple random sampling strategy was also used across the lattice to ensure 
coverage of health states outside of the cluster ConClusions: Previous population 
preference elicitation studies have used theoretical approaches to health states 
elicitation, which could lead to health states being directly valued which are rarely 
experienced in the population. The approach presented here uses the information 
already known about the population, to inform choice of health states for population 
valuation of health using the EQ-5D.
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objeCtives: To describe HUI reference statistics available from clinical and general 
population health studies. Methods: Reviews of published literature, unpublished 
reports and corporate databases were used to identify summary statistics or data 
available for calculation of summary statistics. Published examples illustrate the use 
of HUI reference statistics for health-related quality of life (HRQL) scores to assess the 
health of patients relative to general populations and of general populations between 
countries. Results: Summary statistics of HRQL scores were compiled from pub-
lished clinical studies (n= 5), population health surveys (n= 6), or provided by investiga-
tors of individual studies (n= 3). Statistics from four sets of published results were used 
to identify health problems among patients treated for acute lymphoblastic leukemia 
in childhood in a recently published study. Results from the Joint Canada/US Survey of 
Health (JCUSH), conducted at the same time in both countries using the same survey 
methodology are presented here in brief. The mean HUI3 score in Canada (0.88) was 
slightly higher than in the US (0.87) (p< 0.05). However, the mean HUI3 score for those 
with less than a high school education in Canada (0.81) was much higher than the 
mean for the same group in the US (0.74) (p< 0.05). HUI Mark2 (HUI2) and HUI Mark3 
(HUI3) summary statistics by country, gender, race and age groups are presented in 
43 tables on the HUI web-site (www.healthutilities.com). ConClusions: The results 
highlight the usefulness of continuous preference-based measures of population 
health such as the HUI3. Population reference data enable international comparisons 
of population health and provide normative data with which to interpret results from 
clinical studies. The publicly available summary statistics of interval-scale preference-
based measures for the HRQL of reference populations provide valid, reliable and 
cost-effective results for clinical and general population studies.
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level dynamic Bayesian inhomogeneous Markov model with quarterly time-step 
was then developed to jointly describe prescriptions and outcomes over time 
in relation with adherence proxy using medication possession ratio, adjusting 
for patients demographics and seasonality. Internal and external validation was 
performed. Results: . Such Bayesian model could be fitted to the available data 
with different parameters informed by one or another data source. Treatment 
switches were associated with severity at the previous quarter while adherence 
was significantly improved when patients are switched and when they are less 
controlled in the previous quarter. Risk of exacerbations was depending on the 
control score and season at the present quarter and on the risk of exacerbation 
at the previous quarter. Control was significantly improved by a better adherence 
and to a lesser extent by a treatment escalation and improved severity at the previ-
ous quarter. ConClusions: This Bayesian dynamic model allowed quantifying 
the most important interactions between drug uses and effects on control and 
exacerbations over time, hence providing a powerful tool for real-world outcomes 
predictions in asthma patients.
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objeCtives: Large scale simulation models (e.g. Archimedes Model, MISCAN) are 
increasingly used to predict cost-effectiveness of medical interventions and to 
drive reimbursement decisions. These models are complex and involve hundreds 
of parameters and inputs. Quantification of parameter uncertainties using tradi-
tional sampling-based approaches (e.g., Monte Carlo sampling and its variants) can 
be prohibitively expensive for these models. Methods: We overcome the limita-
tions of traditional probabilistic sensitivity analysis through a 4-step process. First, 
we conduct a thorough survey of all parameters and their confidence intervals. 
Second, we use local sensitivity analysis to evaluate the effects of each parameter 
on the outcome of interest. Third, based on results from single-parameter sensitivity 
analysis, we rank and identify a group of parameters that have the largest effects 
on the outcome. We then employ response surface (RS) approximation methods 
to create a mathematical model of the model predictions for these parameters. 
We use Latin Hypercube sampling (LHS) to generate data points and multivariate 
adaptive regression splines (MARS) to build the response surface approximations. 
Fourth, we sample parameters from their joint distributions, and then use the con-
structed response surface to calculate the probability distribution of the predicted 
outcomes. Results: We apply the above methodology to quantify uncertainties 
in predictions of the Archimedes Model for effectiveness of colorectal cancer (CRC) 
screening by colonoscopy (COLO) and fecal immunological test (FIT). We started out 
with 200 parameters and identified 20 parameters that have significant influences 
on predicted effectiveness of CRC screening. We conclude that there is a 89% chance 
that COLO will save more life years FIT, after accounting for parameter uncertainties. 
Similarly we estimate that there is a 61% probability that FIT is more cost effective 
than colonoscopy. ConClusions: We have developed a robust and efficient meth-
odology for quantifying parameter uncertainties of large-scale simulation models 
used for cost-effectiveness analysis.
ReseARCh on Methods – Patient-Reported outcomes studies
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objeCtives: EQ-5D catalogues have been developed and tested in US and UK. The 
current study aims to develop a Danish preference-based EQ-5D 3L scores cata-
logue for around a hundred of the most common monitored chronic conditions. The 
development is based on experiences from the US and UK, but adding new factors of 
importance such as health habits, BMI, social networks and stress. Methods: The 
marginal disutility estimates will be calculated using CLAD and OLS regression on a 
single source population from a random sample: the National Danish Health Survey 
Data from 2010 which is a self-administrated survey with approx. 38.000 respond-
ents age ≥ 16. The survey data is combined with data from national registers contain-
ing individual health data e.g. diagnosed chronic conditions during hospitalization, 
medication, use of hospitals as well as socio-economic data. The catalogue differs 
from UK and US catalogues’ by adding health habits information and by using ICD-
10 classifications from registers as well as it is based on Danish EQ-5D tariffs. The 
marginal disutility is calculated for each chronic condition controlling for age, gen-
der, ethnicity, income, education and comorbidity etc. Results: Marginal disutility 
estimates (EQ-5D) for around a hundred ICD-10 chronic conditions are presented 
and compared. It is expected that this new knowledge will contribute and qualify 
prioritization debate, when results are published and combined with knowledge of 
for example factors of importance and burden of disease in costs. ConClusions: 
The catalogue will provide scientist with an “off-the-shelf” tool for use in health eco-
nomic evaluations. Marginal disutilities estimates can be used to estimate QALY’s 
in CEA for a wide variety of conditions in Denmark.
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objeCtives: Phosphodiesterase type 5 inhibitors (PDE5i) for the treatment of erec-
tile dysfunction (ED) have similar pharmacologic profile. Patient preferences may 
